The purpose of this study is to evaluate and compare the survival outcome of patients with first recurrence of GBM undergoing surgical debulking/resection followed by either implantation of the SC9 device and repeat BBB opening in association with carboplatin chemotherapy or standard of care second line chemotherapy with either lomustine or temozolomide (per best physician's choice and best practice).
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Dominique Higgins
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Brain and Other Nervous System)
23-2998
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
